Praxis Precision Medicines starts trading on NASDAQ

Cambridge, Massachusetts-based Praxis Precision Medicines, a developer of treatments for central nervous system disorders, has raised about $190 million for its IPO after pricing 10 million shares at $19 per share.

To view this content, you need to sign in.

You should only be asked to sign in once. Not the case? Click here

Register now to access this content and more for free.

Share this